1. DOP87 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn's Disease: Phase 2a APOLLO-CD Study Results. (30th January 2023) Authors: Feagan, B G; Sands, B; Siegel, C A; Dubinsky, M; Longman, R; Sabinho, J; Laurent, O; Luo, A; Lu, J D; Nguyen, D; Towfic, F; DuVall, A; Woyranowski, M; Al Kharrat, H; McGovern, D P B Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i162 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. OP40 PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results. (30th January 2023) Authors: Sands, B; Peyrin-Biroulet, L; Danese, S; Rubin, D T; Vermeire, S; Laurent, O; Luo, A; Nguyen, D; Lu, J D; Wiechowska-Kozlowska, A; Leszczyszyn, J; Kempinski, R; Kierkus, J; Ma, C; Ritter, T; Feagan, B G; Targan, S Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i56 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗